Brief: FDA Approves An Investigational Device Exemption For Spectral Medical PMX To Treat Covid-19 Patients Suffering From Septic Shock
14/04/2020 13:58
April 14 (Reuters) - Spectral Medical Inc EDT.TO :
* US FDA APPROVES AN INVESTIGATIONAL DEVICE EXEMPTION FOR
SPECTRAL
MEDICAL PMX TO TREAT COVID-19 PATIENTS SUFFERING FROM SEPTIC
SHOCK
* SPECTRAL MEDICAL INC - ALSO BEEN ACTIVELY WORKING WITH
HEALTH
CANADA TO EXPEDITE REQUIRED APPROVALS FOR USE IN COVID-19
PATIENTS
Source text for Eikon: ID:nGNX1qvtQw
Further company coverage: EDT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectral Medical
See all newsBrief: Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting For PMX PMA
Canada's Spectral Medical Q2 revenue falls on lower reagent sales
Brief: Spectral Medical And Vantive Announce Topline 12 Month Follow-Up Results From Spectral’S Tigris Trial
Canada's Spectral Medical Q1 revenue rises 56%, net loss narrows
Spectral Medical Q3 revenue up 34%